Use of teriparatide off-label: our experience and review of literature
Author:
- 1 January 2017
- journal article
- review article
- Published by Edikta s.r.l. in Bone Abstracts
- Vol. 14 (1) , 28-34
Abstract
The aim of this paper is to report our experience and to present a review of literature about the use of teriparatide off-label in the therapy of non-unions. Teriparatide is used exclusively in treatment of osteoporosis and to prevent bone fracture because it has a positive effect on bone strength and architecture. The use of teriparatide in non-unions is described as effective in numerous case report.Keywords
This publication has 46 references indexed in Scilit:
- Safety and effectiveness of teriparatide vs alendronate in postmenopausal osteoporosis: a prospective non randomized clinical studyBone Abstracts, 2016
- Teriparatide: an unexpected adjunct for the treatment of a long-standing infected elbow prosthesis prevented arm amputationClinical Rheumatology, 2015
- Parathyroid hormone pulsatility: physiological and clinical aspectsBone Research, 2015
- An atypical fracture in male patient with osteogenesis imperfectaBone Abstracts, 2015
- Atypical Femoral Fracture in an Osteogenesis Imperfecta Patient Successfully Treated with TeriparatideEndocrine Practice, 2014
- Weekly teriparatide administration for the treatment of delayed union: a report of two casesArchives of Osteoporosis, 2014
- Atrophic femoral nonunion successfully treated with teriparatideEuropean Journal of Orthopaedic Surgery & Traumatology, 2012
- Parathyroid Hormone 1-84 Accelerates Fracture-Healing in Pubic Bones of Elderly Osteoporotic WomenJournal of Bone and Joint Surgery, 2011
- PTH Differentially Regulates Expression of RANKL and OPGJournal of Bone and Mineral Research, 2004
- Osteoblastic Cells Mediate Osteoclastic Responsiveness to Parathyroid Hormone*Endocrinology, 1986